Abstract
In September 2006, panitumumab (Vectibix; Amgen), a fully human antibody against the epidermal growth factor receptor (EGFR), was approved by the FDA for the treatment of patients with EGFR-expressing metastatic colorectal cancer with disease progression on or following fluoropyrimidine-, oxaliplatin- and irinotecan-containing chemotherapy regimens.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Identification and super-resolution imaging of ligand-activated receptor dimers in live cells
Scientific Reports Open Access 08 August 2013
-
Humanised IgG1 antibody variants targeting membrane-bound carcinoembryonic antigen by antibody-dependent cellular cytotoxicity and phagocytosis
British Journal of Cancer Open Access 10 November 2009
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Goldberg, R. M. Therapy for metastatic colorectal cancer. The Oncologist 11, 981–987 (2006)
Parkin, D. M. et al. Cancer burden in the year 2000. The global picture. Eur. J. Cancer 37, S4–S66 (2001).
Goldberg. R. M. et al. Cetuxiumab. Nature. Rev. Drug Discov. 4, S10–S11 (2005).
Baselga, J. Why the epidermal growth factor receptor? The rationale for cancer therapy. The Oncologist 7 (S4), 2–8 (2002).
Salomon, D. S. et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol. 19, 183–232 (1995).
Mendez, M. J. et al. Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice. Nature Genet. 15, 146–156 (1997)
Yang, X. D. et al. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res. 59, 1236–1243 (1999).
Yang, X. D. et al. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit. Rev. Oncol. Hematol. 38, 17–23 (2001)
FDA labelling information [online], <http://www.fda.gov/cder/foi/label/2006/125147s0000lbl.pdf> (2006).
Yarden, Y. & Sliwkowski, M. X. Untangling the ErbB signalling network. Nature Rev. Mol. Cell Biol. 2, 127–137 (2001).
Hurwitz, H. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335–2442 (2004).
Saltz, L. et al. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc. Am. Soc. Clin. Oncol. 20, A7 (2001).
Saltz, L. B. et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol. 22, 1201–1208 (2004).
Tabernero, J. et al. Optimal dose of cetuximab (C) given every 2 weeks (q2w): A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly (q1w) and q2w schedules in patients (pts) with metastatic colorectal cancer (mCRC). J. Clin. Oncol. 24, 18S (2006).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Saltz, L., Easley, C. & Kirkpatrick, P. Panitumumab. Nat Rev Drug Discov 5, 987–988 (2006). https://doi.org/10.1038/nrd2204
Issue Date:
DOI: https://doi.org/10.1038/nrd2204
This article is cited by
-
Identification and super-resolution imaging of ligand-activated receptor dimers in live cells
Scientific Reports (2013)
-
Pharmacogenetics and pharmacogenomics: role of mutational analysis in anti-cancer targeted therapy
The Pharmacogenomics Journal (2012)
-
Humanised IgG1 antibody variants targeting membrane-bound carcinoembryonic antigen by antibody-dependent cellular cytotoxicity and phagocytosis
British Journal of Cancer (2009)
